CINV is a common side-effect of many antineoplastic regimens and can occur for several days after treatment. FDA has approved rolapitant in 2015 for prevention of delayed nausea and vomiting associated with chemotherapy. It blocks the actions of chemicals in the body that trigger nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) affect almost 90 % of patients receiving chemotherapy and can have a significant impact on patients quality of life, compromising, patients compliance with therapy, leading to dose reductions, treatment delay or discontinuation of therapy. Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist, approved for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. It is mainly used for prevention of CINV caused due to highly emetogenic chemotherapy and moderately emetogenic…
